Suzetrigine Approval Breaks a 25-Year Silence: A New Era in Non-Opioid Acute Pain Management

Olivier Sibomana,1,2 Melody Okereke,3 Clyde Moono Hakayuwa4 1Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda; 2Department of Research, OLGNova, Kigali, Rwanda; 3Faculty of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria; 4Department of Public Health, Copperbelt University, Ndola, ZambiaCorrespondence: Olivier Sibomana, Email [email protected]: Pain management remains a critical priority in clinical practice. Meanwhile, traditional analgesics, including non-opioid and opioid medications, often pose substantial risks, including adverse effects and potential for addiction. The recent approval of Suzetrigine by the US Food and Drugs Administration (FDA) represents a pivotal advancement in non-opioid analgesia for the treatment of moderate-to-severe acute pain. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, provides effective pain relief by targeting peripheral pain pathways, minimizing the risk of addiction commonly associated with opioids, and has good safety profile according to clinical trials. Given the growing concerns surrounding opioid use, Suzetrigine offers a promising therapeutic alternative in acute pain management, with future research needed to assess its long-term effectiveness in diverse populations.Keywords: analgesics, pain, drugs, opioids, pharmacology